Management
Bo Rode Hansen
Chief Executive Officer
MSc, Ph.D., MBA
Previously: President and CEO of Genevant Sciences Inc.; Global Head of Roche RNA Therapeutics & General Manager of Roche Innovation Center Copenhagen; Executive, VP & Head of Drug Discovery & Alliance at Santaris (acquired by Roche).
Scandion Oncology shares and warrants
25.173 shares and 1.071.688 warrants
Nils Brünner
Chief Scientific Officer
MD, DMSc.
Professor University of Copenhagen.
Co-founder of Scandion Oncology A/S.
Scandion Oncology shares and warrants
1.089.916 shares (Partly owned via Timpco NB ApS)
Carit Andersen
Chief Financial Officer
MSc (Econ.)
External lecturer, University of Southern Denmark.
Scandion Oncology shares and warrants
65.360 shares and 53.584 warrants (Partly owned via Decisionconsult Holding ApS)
Jan Stenvang,
Chief Technology Officer
MSc, PhD.
Associate Professor, University of Copenhagen.
Co-founder of Scandion Oncology A/S.
Scandion Oncology shares and warrants
1.391.519 shares
Peter Michael Vestlev
Chief Medical Officer
MD, CBA, MPP.
Chief Physician, Oncologist, Region Sjælland.
Previously, consultant for the Danish Medicines Agency.
Scandion Oncology shares and warrants
140.297 shares and 53.584 warrants
Nicklas Lindland Roest
Chief Regulatory Officer
MSc. Pharm.
Scandion Oncology shares and warrants
30.688 shares and 53.585 warrants (Partly owned via Lindland Roest Holding ApS)
Annie Rasmussen
Chief Clinical Officer
RN, Master of Public Health
Scandion Oncology shares and warrants
18.795 shares and 53.585 warrants
Pipeline
Scandion Oncology has two promising compounds in the pipeline. SCO-101, our most advanced lead candidate, is in clinical Phase I and II studies and SCO-201 is in preclinical testing. We expect to deliver proof-of-concept with SCO-101 in 2022. Scandion Oncology is building a pipeline of drugs that can revert anti-cancer drug resistance through different mechanisms. The aim is to increasingly broaden the offering of medicines able to combat anti-cancer drug resistance.
Clinical Trials
Our first-in-class lead compound SCO-101 has been shown to enhance the effect of certain standard chemotherapies when given in combination. Scandion Oncology has two programs in clinical development with SCO-101. The most advanced program, CORIST, for the treatment of drug resistant metastatic colorectal cancer is in clinical Phase II studies. The second program, PANTAX, for the treatment of inoperable or metastatic pancreatic cancer is in clinical Phase Ib studies.
Investors
Detailed analyses suggest the market for Scandion Oncology’s products to be more than EUR 4 billion annually.
We believe our programs could be attractive for various pharmaceutical companies to combine with their anti-cancer treatments.
Co-funded by the Horizon 2020 programme of the European UnionCo-funded by the COSME programme of the European Union